Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Subscribe
Pharma
Vaccines
Asia
Cell & Gene Therapy
Drug Delivery
Executives
Manufacturing
Facilities
Recalls
Warning Letters
Marketing
Special Reports
Fierce 50
Special Report
Awards Gala
Trending
Oncology
Supply Chain
Awards
CRO Awards
Innovation Awards
Pharma Marketing Awards
Resources
Podcasts
Fierce Events
Industry Events
Webinars
Whitepapers
Survey
Events
Subscribe
Fierce Pharma
Fierce Biotech
Fierce Healthcare
Fierce Life Sciences Events
Advertise
About Us
PrEP
Pharma
Gilead lifts guidance on PrEP launch despite cell therapy woes
Gilead’s long-acting pre-exposure prophylaxis med Yeztugo has garnered $54 million in sales since its June launch in the U.S., the company reported.
Zoey Becker
Oct 31, 2025 11:51am
GSK touts study showing tolerability edge for its long-acting PrEP
Oct 15, 2025 8:45am
Celltrion buy, Rexulti CRL, Glenmark-Hengrui—Fierce Pharma Asia
Sep 26, 2025 10:00am
CDC 'strongly recommends' Gilead's HIV PrEP Yeztugo
Sep 19, 2025 11:22am
RFK Jr.'s potential USPSTF revamp may threaten PrEP makers
Jul 28, 2025 11:22am
Lilly's Kisunla, Gilead's PrEP drug Yeytuo gain CHMP nods
Jul 25, 2025 11:03am
